Safety, Efficacy, and Effectiveness of Live, Attenuated, Cold‐Adapted Influenza Vaccine in an Indicated Population Aged 5–49 Years
- 1 October 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (7) , 920-927
- https://doi.org/10.1086/423001
Abstract
Background. Three important studies have supported licensure of live, attenuated, cold-adapted influenza vaccine (CAIV-T [FluMist; MedImmune Vaccines]): (1) a pediatric efficacy trial involving children 15–71 months of age, (2) a large safety study of medically attended events occurring among children 1–17 years of age, and (3) an effectiveness trial involving healthy working adults 18–64 years of age.Keywords
This publication has 6 references indexed in Scilit:
- Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescentsThe Pediatric Infectious Disease Journal, 2004
- Effectiveness and Cost-Benefit of Influenza Vaccination of Healthy Working AdultsJAMA, 2000
- Prevention of otitis media in children with live attenuated influenza vaccine given intranasallyThe Pediatric Infectious Disease Journal, 2000
- Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccineThe Journal of Pediatrics, 2000
- Effectiveness of Live, Attenuated Intranasal Influenza Virus Vaccine in Healthy, Working AdultsJAMA, 1999
- The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in ChildrenNew England Journal of Medicine, 1998